Evidence map›Paper›PMID 25781618›Full record

Trial reportPloS one2015

Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.

Eleonora Riccio, Massimo Sabbatini, Dario Bruzzese, Ivana Capuano, Silvia Migliaccio, Michele Andreucci, Antonio Pisani

Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01768351 (Direct Effect of Paricalcitol on Anemia in Chronic Kidney Disease), which is not on this map. Cited by 23 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 5 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01768351 phase4completednot on this map

Direct Effect of Paricalcitol on Anemia in Chronic Kidney Disease

TypeinterventionalSponsorFederico II UniversityRan2010 to 2012Enrolled60ConditionsAnemia, Chronic Kidney DiseaseArmsParicalcitol, Calcitriol
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. High-Dose Vitamin DJPEN. Journal of parenteral and enteral nutrition · 2018
    Trial
  8. High-dose vitamin DClinical nutrition (Edinburgh, Scotland) · 2017
    Trial
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Eleonora RiccioChair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.
Massimo SabbatiniChair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.
Dario BruzzeseChair of Statistics, Department of Public Health, University Federico II of Naples, Naples, Italy.
Ivana CapuanoChair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.
Silvia MigliaccioChair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.
Michele AndreucciUnit of Nephrology, University Magna Graecia, Catanzaro, Italy.
Antonio PisaniChair of Nephrology, Department of Public Health, University Federico II of Naples, Naples, Italy.
Magna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies suggest that vitamin D deficiency represents an additional cofactor of renal anemia, with several mechanisms accounting for this relationship. In line with it, the administration of vitamin D or its analogues has been associated with an improvement of anemia. There are no data, however, about a direct effect of paricalcitol on hemoglobin (Hb) levels. Therefore, we conducted a study to determine whether paricalcitol, compared to calcitriol, improves anemia in patients with chronic kidney disease (CKD).

methodsIn this randomized trial 60 CKD patients stage 3b-5 and anemia (Hb levels: 10-12.5 g/dL) were assigned (1:1) to receive low doses of calcitriol (Group Calcitriol) or paricalcitol (Group Paricalcitol) for 6 months. All the patients had normal values of plasma calcium, phosphorus and PTH, a stable iron balance, and normal values of C-Reactive Protein. The primary endpoint was to evaluate the effects of the two treatments on Hb levels; the modifications in 24hr-proteinuria (UProt) were also evaluated.

resultsA significant Group x Time interaction effect was observed in the longitudinal analysis of Hb levels (F(1,172)=31.4, p<0.001). Subjects in Paricalcitol experienced a significant monthly increase of Hb levels equal to +0.16 g/dL [95% C.I. 0.10 to +0.22, p<0.001) while in Group Calcitriol, Hb decrease throughout the follow-up with an average monthly rate of -0.10 g/dL (95% C.I.: -0.17 to -0.04, p<0.001). In Group Paricalcitol, UProt was significantly reduced after 6 months [0.35 (0.1-1.2) vs 0.59 (0.2-1.6), p<0.01], whereas no significant difference emerged in Group Calcitriol. Plasma levels of calcium, phosphate, PTH and of inflammation markers remained in the normal range in both groups throughout the study.

conclusionsShort-term exposure to paricalcitol results in an independent increase in Hb levels, which occurred with no modification of iron balance, inflammatory markers, and PTH plasma concentrations, and was associated with a decrease in UProt.

trial registrationClinicalTrials.gov NCT01768351.

Indexed as

CalcitriolC-Reactive ProteinErgocalciferolsFemaleFollow-Up StudiesHemoglobinsHumansMaleMiddle AgedRenal Insufficiency, ChronicTreatment OutcomeCalcitriolC-Reactive ProteinErgocalciferolsHemoglobinsparicalcitol

Identifiers

PMID25781618
PMCPMC4363688
OpenAlexW2014548325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.